Actelion Ltd.

139 articles with Actelion Ltd.

• Arkivum Provides Pioneering e-Archive to Idorsia Pharmaceuticals Delivering GxP Compliant Long-term Access to Valuable Product and Clinical Trial Data

  9/3/2019

  Arkivum announced that Idorsia Pharmaceuticals, headquartered near Basel, Switzerland; has selected Arkivum to safeguard and digitally preserve their valuable research and clinical trial data.

• 

  Actelion, a J&J Division, Ponies up $360 Million to Settle U.S. Kickback Charges

  12/7/2018

  The government alleged Actelion provided money to a nonprofit to cover copay costs for Medicare drugs, a violation of the False Claims Act.

• Helsinn Group announces agreement to acquire worldwide rights to Valchlor/Ledaga, an approved and marketed alkylating agent for topical treatment of mycosis fungoides type cutaneous T-cell lymphoma

  3/21/2018

  Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma, a rare type of skin cancer.

• Cancellation of Publicly Held Actelion Shares and Delisting From SIX Swiss Exchange as of November 7, 2017

  10/31/2017

  The holders of the cancelled Actelion Shares will be paid a cash compensation in the amount of $280 for each cancelled Actelion Share.

• Actelion Receives FDA Approval Of TRACLEER (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension

  9/6/2017

• Johnson & Johnson Completes Acquisition Of Actelion

  6/16/2017

• Johnson & Johnson Announces Completion Of Acquisition Of Actelion

  6/16/2017

• As Johnson & Johnson Closes $30 Billion Deal, Actelion Spinoff Is Valued at $1.54 Billion In IPO Debut

  6/16/2017

• Johnson & Johnson Announces Expected Settlement Of Actelion Tender Offer On June 16, 2017

  6/9/2017

• Actelion Reports Good And Bad News For Phase III CDAD Trials

  6/8/2017

• Actelion Provides An Update On The Progress Towards Launching Idorsia - Key Results For Pipeline Assets To Be Developed By Idorsia

  5/22/2017

• Actelion Announces Changes To Its Executive Team Upon Completion Of The Transaction With Johnson & Johnson

  5/15/2017

• Publication Of The Definitive Notice Of The End Result Of Actelion Tender Offer

  4/27/2017

• Publication Of The Provisional Notice Of The End Result Of Actelion Tender Offer

  4/24/2017

• Actelion's R&D Discovery Biz Gets a Name, Idorsia

  3/15/2017

• So Close, Yet So Far Away: How Sanofi Lost to Johnson & Johnson in the Epic $30 Billion Battle for Actelion

  2/16/2017

• Johnson & Johnson Publishes Prospectus For Actelion Tender Offer

  2/16/2017

• Despite Losing Out on Actelion, Sanofi in No Hurry to Make Deals

  2/8/2017

• It's Finally Happening: Johnson & Johnson Pays $30 Billion for Actelion, Will Spin Off R&D Unit With $1 Billion Cash

  1/27/2017

• How a Johnson & Johnson Corporate Jet Had Hedge Funds Betting Big on an Actelion Deal

  1/27/2017